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Checkpoint immunotherapeutics are promising agents
with potential to improve patient outcomes in several
cancer types. Unfortunately, to date, single agent immu-
notherapy has achieved limited clinical benefit in patients
with pancreatic ductal adenocarcinoma (PDAC). This
may be due to the presence of the uniquely immunosup-
pressive tumor microenvironment present in PDACs that
creates a barrier to immune surveillance by T cells. Criti-
cal obstacles to immunotherapy in PDAC tumors include
the dense desmoplastic stroma that acts as a barrier to
T cell infiltration and high numbers of tumor-associated
immunosuppressive cells, such as MDSCs and regulatory
T cells (Tregs).
To understand which signaling pathways in pancreatic
tumor cells might drive this suppressive tumor microen-
vironment, we analyzed the correlation between hyper-
activated signaling molecules and tumor infiltrating
leukocytes using 50 human PDAC tumor tissues. Of the
pathways evaluated, we found that focal adhesion kinase
(FAK) activity is elevated in human PDAC and that
FAK activity correlates with highly fibrotic tumors with
poor CD8+ T cell infiltration. The oral FAK kinase inhi-
bitor VS-4718, currently in Phase I clinical evaluation,
was tested to determine if it could overcome the immu-
nosuppressive tumor microenvironment of PDAC. Sin-
gle agent VS-4718 dramatically limited tumor
progression resulting in a doubling of survival in the
p48-CRE/KrasG12D/p53flox/+ PDAC mouse model (KPC
mice). This alteration in tumor progression was asso-
ciated with dramatically reduced tumor fibrosis,
decreased numbers of FOXP3+ Tregs and tumor-infil-
trating myeloid cells, and anti-tumor polarization of
tumor-associated macrophages.
We postulated that the desirable effects of FAK inhibi-
tion on the tumor microenvironment might render PDAC
tumors more sensitive to immunotherapy. Accordingly,
we found that VS-4718 significantly potentiated the effi-
cacy of anti-PD-1 and anti-CTLA4 antibodies in KPC
mouse models nearly tripling survival times. We next
assessed the mechanism of this potentiation. We found
that FAK in tumor cells regulates pro-inflammatory and
pro-fibrotic cytokine secretion. Furthermore, we found
that shRNA knockdown of FAK in PDAC cells results in
failure of PDAC cells to induce pro-fibrotic programs in
fibroblasts. Importantly, the FAK inhibitor VS-4718 and
FAK shRNA in the tumor cells were each effective in
increasing CD8+ cytotoxic T cell infiltration into the
PDAC tumors in vivo. Taken together, these data suggest
that FAK inhibition increases immune surveillance
programs in PDAC tumors by overcoming the fibrotic and
inflammatory microenvironment rendering tumors more
responsive to immunotherapy. These data provide ratio-
nale for clinical evaluation of a FAK inhibitor in combina-
tion with a PD-1 or PD-L1 antibody in patients with
pancreatic and other cancers.
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